title: Vascular rejection and its relationship to allograft coronary artery disease.
abstract: We have prospectively monitored 268 patients by our previously described method of routine immunofluorescence of endomyocardial biopsy specimens. We have classified these patients according to their rejection pattern: cellular, vascular, and mixed. The criteria for these designations have been previously described. In this study we retrospectively reviewed coronary angiograms of these patients to assess the presence and time-course of developing allograft coronary artery disease. All available explanted hearts and postmortem hearts were also assessed by light microscopic examination for acute coronary vasculitis and allograft coronary artery disease and by immunofluorescent microscopy for vascular immune complex deposition in a manner identical to immunofluorescent microscopic examination of endomyocardial biopsy specimens. Patients were also monitored for sensitization to immunoprophylactically administered murine monoclonal CD3 antibody (OKT3) and those demonstrated to be sensitized were separately analyzed. Clinical features and treatment of patients were retrospectively reviewed. We found that 141 patients could be classified as having cellular rejection, 76 as having vascular rejection, and 52 as having a mixed rejection pattern. The allograft survival in vascular rejection patients was significantly worse than in allografts of patients with cellular or mixed rejection, confirming our earlier results. Most importantly, we found a significant difference in the time to the development of allograft coronary artery disease based on the rejection pattern. This difference existed whether or not patients sensitized to OKT3 were excluded from evaluation. Patients with mixed rejection had an intermediate time to the development of allograft coronary artery disease between that of patients with cellular and vascular rejection.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine, Salt Lake City 84143.
authors.forename: E H
authors.initials: EH
authors.lastname: Hammond
authors.forename: R L
authors.initials: RL
authors.lastname: Yowell
authors.forename: G D
authors.initials: GD
authors.lastname: Price
authors.forename: R L
authors.initials: RL
authors.lastname: Menlove
authors.forename: S L
authors.initials: SL
authors.lastname: Olsen
authors.forename: J B
authors.initials: JB
authors.lastname: O'Connell
authors.forename: M R
authors.initials: MR
authors.lastname: Bristow
authors.forename: D B
authors.initials: DB
authors.lastname: Doty
authors.forename: R C
authors.initials: RC
authors.lastname: Millar
authors.forename: S V
authors.initials: SV
authors.lastname: Karwande
mesh_terms: D003327:Coronary Disease / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011183:Postoperative Complications / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D011446:Prospective Studies
chemical_list: D006684:HLA-DR Antigens; D016853:Muromonab-CD3